Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab combined with isotretinoin for severe acne and acne conglobata
ChiCTR2100043791Phase 4Recruiting
- Sponsor
- Southern Medical University Dermatology Hospital
- Start
- Mar 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of adalimumab and isotretinoin in acne vulgaris and acne conglobata (AC) (2 arms), sponsored by Southern Medical University Dermatology Hospital. Primary endpoints: Global Acne Grading System, Drug tolerability assessment and 4 more. Started Mar 2021; status: recruiting.
02
Drugs
adalimumabisotretinoin
03
Conditions
acne vulgarisacne conglobata (AC)
Beyond the preview
Go deeper on ChiCTR2100043791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100043791.